These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: South Africa says it can't afford anti-AIDS drug AZT.
    Journal: AIDS Wkly; ; ():20-1. PubMed ID: 12349345.
    Abstract:
    Health Minister Manto Tshabalala-Msimang announced that South Africa could not afford the anti-AIDS drug azidothymidine (AZT) as treatment for the 4 million South Africans inflicted with the disease. She said that the cost of the triple therapy drugs alone, which is around $47 billion annually, would be 10 times the total South African health care budget. Her ministry is also still awaiting the results of the drug review that was conducted after President Thabo Mbeki expressed his doubt over the drug's usefulness. The country would however continue to look for clinically effective and cost-effective treatment for HIV/AIDS. The drug's manufacturer, Glaxo Wellcome, on its part, refutes doubts about AZT and even offered the drug to South Africa at 70% less than its open market price. Furthermore, opposition parties in parliament also urged the government to reconsider its stand on AZT.
    [Abstract] [Full Text] [Related] [New Search]